In Brief: Biomatrix' Hylaform
This article was originally published in The Gray Sheet
Executive Summary
Biomatrix' Hylaform: Plans to withdraw a pre-market approval application for its viscoelastic gel, which is designed for use in removing depressed scars and facial wrinkles, the company says in a Dec. 31 release. The firm, which anticipates revising and resubmitting the PMA, is seeking to schedule a January meeting with FDA to discuss the need for additional skin test data on allergic reactions and labeling changes. Hylaform is marketed in Europe by Collagen Corp.; the product gained the CE mark in December 1995. Biomatrix submitted a PMA to FDA in August of that year ("The Gray Sheet" Oct. 2, 1995, in brief)...
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.